Related Experiment Video
Updated: Jul 5, 2025
09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
344
KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells
Ranjan Devkota1, Jonnell C Small1, Kaycee Carbone1
1Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA.
Diabetes
|January 11, 2024
Summary
The small molecule KD025 protects pancreatic beta cells from glucolipotoxicity (GLT) by inhibiting casein kinase 2 (CK2), not ROCK2. This finding offers a new therapeutic strategy for type 2 diabetes.
Area of Science:
- Endocrinology
- Molecular Biology
- Pharmacology
Background:
- Glucolipotoxicity (GLT) contributes to type 2 diabetes by harming pancreatic beta cells.
- KD025 was initially identified as a potential protector against GLT, inhibiting ROCK2.
Purpose of the Study:
- To elucidate the precise mechanism by which KD025 protects beta cells from GLT.
- To investigate the role of ROCK2 and identify other potential targets of KD025.
Main Methods:
- Kinase profiling to identify KD025 targets.
- Pharmacological and genetic inhibition of ROCK2.
- Experimental verification of CK2 inhibition on cell viability under GLT conditions.
Main Results:
- KD025's protective effects against GLT were independent of ROCK2 inhibition.
- Kinase profiling revealed KD025 as a potent inhibitor of casein kinase 2 (CK2).
- Inhibition of CK2A1, a CK2 subunit, enhanced beta cell viability during GLT.
Conclusions:
- KD025 protects pancreatic beta cells from glucolipotoxicity through the inhibition of casein kinase 2 (CK2).
- This mechanism differs from its previously assumed ROCK2 inhibition pathway.
- Targeting CK2 represents a potential therapeutic avenue for managing type 2 diabetes.
More Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
01:24Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
01:05Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K